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1I n t r o d u c t i o n
Imperfect information often results in “Principal-agent problems” when one
person, the agent, is employed to act on behalf on another, the principal (Ross,
1973). In the healthcare sector the problem is complex since eﬃciency requires
physicians to act not only as agents for their patients, but also for third-party
payers, insurers (Blomqvist, 1991, and Shortell, 1998). This study analyzes how
economic incentives aﬀect physicians’ decisions whether or not to veto generic
substitution, and also whether their decisions suggest that they internalize dif-
ferently the costs occurring to their two principals.
Since October 2002, pharmacists in Sweden have been required to substi-
tute the prescribed pharmaceutical product to the cheapest available generic
when neither the prescribing physician nor the patient oppose it. Patients who
oppose substitution have to pay the diﬀerence in price themselves, but if the
physician vetoes it for medical reasons, they are subject only to the normal
copay requirement under Swedish pharmaceutical insurance.
Although similar reforms have been introduced in many European countries
and American states, what determines whether physicians’ veto substitution
has, to my knowledge, not been studied previously.1 This is an important issue
because physicians’ decisions not only directly aﬀect patients’ and insurers’ costs
for pharmaceuticals, but also indirectly since more bans against substitution
likely reduces price-competition between pharmaceutical ﬁrms.2 In the sample
used for this study, brand-name products for which substitution was vetoed by
physicians were on average 218% more expensive than the cheapest generic al-
ternative; whereas the corresponding ﬁgure for other brand-name products was
only 15%. This correlation might indicate that physicians’ decisions whether or
not to veto generic substitution have an important eﬀect on price-competition
among pharmaceutical ﬁrms, but this warrants further research.
The primary purpose of this study was to analyze whether privately em-
ployed physicians were more or less inclined to oppose substitution, compared
1One explanation could be lack of data: Hellerstein (1998) noted that the US NAMCS-
data unfortunately lack information about whether substitution was vetoed, while Mossialoa,
Walley and Rudisill (2005) noted on a general scarcity of good prescription data for several
European countries.
2Granlund and Rudholm (2007) analyzed the eﬀect on price-competition and pharmaceu-
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to county-employed physicians. Private physicians have a stronger incentive to
please their patients in order to keep them, since their income depends on the
number of patient-visits, whereas county physicians work on salary. Oppos-
ing substitution, if the patient suggests that, might be a costless way of doing
this. Allowing substitution might also be time-consuming for the physician if
it worries the patient. Hence, each consultation could take longer, resulting
in fewer of them, and again less income. Private physicians might also have
stronger brand-name loyalty since, for example, they are less restricted, com-
pared to county-employed physicians, from participating in education organized
and paid for by pharmaceutical companies. The hypothesis to be tested is thus
that private physicians were more likely than county physicians to veto substi-
tution.
Another purpose was to analyze the eﬀect of patients’ copayments on physi-
cians’ decisions. The Swedish pharmaceutical insurance is non-linear, with
patient-copayments decreasing as total expenditure increases. This provided
an opportunity to study whether physicians internalized patients’ costs more
than costs to the insurer, indicating moral hazard in insurance (Pauly, 1968).3
The analyses were done using a sample of 350,000 observations drawn from
a micro-dataset covering all prescriptions dispensed in the county of Västerbot-
ten, Sweden - or dispensed elsewhere in Sweden to inhabitants of Västerbotten
- during 43 month after the substitution reform. The dataset includes infor-
mation about the patients, prescribers, prices, copayments, pharmaceuticals
prescribed and dispensed, and about whether the physician or patient opposed
substitution.
Since the values were observed at micro-level, the risk of estimators being
biased towards zero was reduced; this is otherwise a common problem when
aggregated data are used as proxies for mirco-variables.4 Using register-data
also eliminated recall-bias, as well as selection-bias, which can be a problem if for
example not everyone participates in an experiment or answers a questionnaire.
The size of the dataset also substantially reduced the risk of accepting a false
null-hypothesis which is otherwise a common problem when studying questions,
3Moral hazard in insurance is also called ex post moral hazard, to distinguish it from moral
hazard referring to changed risk behavior.
4Proxy variables can be seen as measurements with errors of the micro-variables. Greene
(2003, Chapter 5) describes how measurement errors lead to bias towards zero, so called
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such as here, where a large part of the variation, for various reasons, cannot be
explained by the observables.
Gosden, Pedersen and Torgerson (1999) reviewed the literature on the eﬀects
of salary payments on physicians’ behavior. They reported some evidence that
payments of salary was associated with fewer referrals and tests compared both
with fee-for-service (FFS) payments and capitations. Compared with FFS pay-
ments, salary payment also correlated with fewer procedures per patient, fewer
patients per physician, longer consultations, more preventive care, and diﬀerent
patterns of consultation. Nassiri and Rochaix (2006) found that primary-care
physicians in Quebec reacted both to temporary removal of expenditure caps
and to changes in the relative price of consultations by changing their treat-
ment pattern. Dusheiko et al. (2006), studying the eﬀect of ﬁnancial incentives
on general medical practices in England, found that abolishing foundholding
increased elective surgery by 3-5%.
The theoretical analysis here follows Hellerstein (1998) and Lundin (2000)
who both - as well as Leibowitz, Manning and Newhouse (1985) - studied the
choice between prescribing brand-name or generic pharmaceuticals. Using U.S.
data, the ﬁrst and third study found that the choice was not a function of the
insurance plan.5 On the other hand, using a Swedish dataset covering seven
pharmaceuticals, Lundin found evidence of moral hazard: Patients with low
copayments were more likely to receive brand-name pharmaceuticals. Crown
et al. (2004) found no statistically signiﬁcant eﬀect of insurance plans’ mean
copayment-rates on patients’ treatment patterns for asthma. However, Rud-
holm (2005) found signiﬁcant eﬀects of individual patients’ copayment-rates on
both quantities dispensed and price. Rudholm also included a variable indi-
cating for privately employed physicians in his regressions but, except in one
subsample, found no statistically signiﬁcant eﬀects of this variable.
Empirical results presented in this paper show that physicians were more
likely to oppose substitution if they were privately employed and the lower the
patients’ copayment-rates were. However, the likelihood of private physicians
vetoing substitution was not found to increase faster than that for county-
employed physicians when patients’ copayment-rates decreased. According to
the theoretical model, this implies that private physicians’ higher likeliness to
5However, Leibowitz, Manning and Newhouse found that individuals with more generous
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veto substitution was caused by them having higher direct costs associated with
substitution rather than stronger incentives to please their patients.
The next section describes the compensation of private and county-employed
physicians in the county of Västerbotten, as well as the Swedish pharmaceutical
insurance system. Section 3 presents the theoretical model. The data are dis-
cussed in section 4.1, the empirical speciﬁcation in section 4.2, while section 4.3
contains the results. Finally, in section 5 the paper’s conclusions are presented.
2 Rules and incentives
2.1 Physicians and their compensation
There were nearly 1000 physicians working in the county of Västerbotten dur-
ing the study-period. Most of them were county-employed, paid on salary,
but nearly 40 physicians worked at small private practices, indicated here as
Private.6
Twenty of the private physicians worked at practices that were nevertheless
paid by the county council, according to three diﬀerent types of contract, while
the remainder were paid privately, either directly by patients, or possibly under
contract to private health insurance companies.7 The most common type of
county-council contract stipulated fee-for-service reimbursement, according to
the so called national rate (Nationella taxan). The second type, individually
negotiated contracts, also stipulated ﬁxed compensation per procedure. All
practices paid according to these two types of contracts were single practices.
Finally, four physicians worked at two so called “house-doctor practices”, which
were paid fee-for-service plus a capitation per patient registered at their practice.
All three types of contract stipulated that compensation increased with the
number of patient-visits. The compensation-schemes were nonlinear however:
Compensation per procedure was reduced if the practice reached certain break-
points. All contracts also stipulated that, for practices to receive compensa-
tion from the county, they were not allowed to charge higher copayments for
6The National Board on Health and Welfare estimated the number at 37 in 2005. In
addition ﬁve physicians worked at private occupational health services, excluded from this
analysis.
7In the data it is possible to identify whether a prescription was written by a private
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patient-visits than did the public healthcare providers. Hence, for all these
publicly-ﬁnanced physicians, price was essentially ﬁxed, and their only compe-
tition variable was quality.
There were also physicians working in other organizational forms, including
ten working for the private company Carema, which ran Dragonen’s health cen-
ter during the last ﬁve months of the study-period. Carema received a lumpsum
payment for the ﬁrst 12 months, after which compensation would depend on the
number of registered patients at the health center. The incentives for physicians
working for Carema probably diﬀered from those for other private physicians
in two ways: The incentives for the company diﬀered from those for private
practices and then there were probably internal principal-agent problems.8
2.2 Patients’ copayments and the substitution reform
In the Swedish pharmaceutical insurance system patients pay costs up to 900
Swedish crowns per 12-month period; 50% of the cost from 900 to 1700 SEK;
25% from 1700 to 3300 SEK; and 10% from 3300 to 4300 SEK; after which
all costs during the period are paid by the insurance (speciﬁcally, by Swedish
county councils). However, there are some exceptions: Some pharmaceuticals
are always free of charge for the patient, and others are not covered by insurance
at all.
Another exception is because of the substitution reform that came into eﬀect
October 1, 2002. The reform (Lag 2002:160) requires that pharmacists inform
8Another organizational form is the so-called community company, which ran Jörn’s health
centre since October 2003 with two part-time physicians. The company received its compen-
sation in ﬁxed lumpsum payments. The incentives for this health center therefore seem similar
to those of the health centers managed by the county council. In addition, there were two
personnel-managed health centers with greater autonomy from the county council, which were
also compensated by lumpsum payments. Granlund, Rudholm and Wikström (2006) found
no clear eﬀect of increased autonomy on the prescription-behavior of physicians working at
these health centers. Therefore, these centers, and Jörn’s health center were treated in the
empirical analysis here as ordinary county health centers. I tried including indicator-variables
for prescriptions written at Jörn’s health centre and at the personnel managed health cen-
ters, but the odds-ratios for these variables were not signiﬁcantly diﬀerent from unity, and
the qualitative results were not aﬀected by including them. By qualitative results I mean
that the odds-ratios for Private and for the four copayment variables are signiﬁcantly above
unity, and that the point estimates for the copayment-variables monotonically increased as
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patients when there are substitutes available, and that the cheapest available
generic product considered to be a perfect substitute by the Swedish Medical
Products Agency would be provided within the Swedish pharmaceutical insur-
ance system.9 Patients need not accept substitution, but the entire extra cost
will then be charged to them.10
Physicians can veto substitution for medical reasons, in which case the extra
cost is covered by the pharmaceutical insurance system. Thus, patients who
would otherwise refuse substitution could save money if their physician opposed
it instead, given that their pharmaceutical cost for that 12-month period was
more than 900 SEK. As total pharmaceutical cost goes up, patients could save
more if their physician vetoed substitution; above 4300 SEK total cost, they
would pay nothing if their physician opposed substitution, versus paying the
entire diﬀerence themselves.
Of course, patients who would not refuse substitution could have lower co-
payments if their physician allowed substitution. If there is no medical reason
against substitution, physicians will generally agree to it for such patients, given
that their direct cost for this (discussed below) is not too high, since there is
then no conﬂict between the rules physicians should follow and the patient’s
interest.
3 Theoretical model
The physician chooses which pharmaceutical to prescribe and whether or not
to veto substitution. If the physician does not veto, the patient then decides
whether or not to refuse substitution. The equations below aim to describe how
patients’ and physicians’ utilities are aﬀected by a veto against substitution.11
9All pharmaceuticals in Sweden are sold through a nationwide government-owned
monopoly.
10Some employees were covered by supplemental medical insurance for prescription drugs,
provided by their employer. (According to Lundin, 2000, 10% of the employees were covered
by such insurances in 2000.) However, even if the entire out-of-pocket cost were covered
by such extra insurance, the cost was not reduced to zero for the patient, since such fringe
beneﬁts were subject to taxation. Also, many patients were retired (45% in the dataset used
here) and thus not covered by extra insurance.
11The model is inspired by Hellerstein (1998) and Lundin (2000).Does physicians’ compensation aﬀect the probability ... 7
The patient’s utility function is written
Up = H +( Y − costp),( 1 )
where H is monetized health; Y is income; and costp is the patient’s mone-
tary cost for the pharmaceutical consumed. Thus (Y − costp) represents the
utility that the patient obtains from consumption of other goods. Let ∆P be
the price-diﬀerence between the prescribed pharmaceutical and the cheapest
generic, and E[∆H] be the patient’s expectation of the resulting diﬀerence in
health outcomes. The patient will then refuse substitution if E[∆H] > ∆P.12
The physician’s utility function is written as
Uph = γ1H − γ2costp − γ3costin − γ4c,( 2 )
where γ1, γ2, γ3 and γ4 are the weighs the physician puts on the health of
the patient, the patient’s monetary cost, the insurer’s monetary cost (costin)
and the physician’s own direct cost (c). The physician might internalize the
consequences for the patient because of altruistic considerations, or because
of pecuniary incentives. Pecuniary incentives could arise, for example, since
patients can change physician if they are not satisﬁed. The last term, c,i s
a direct cost that the physician might experience from allowing substitution,
for example if it raises questions from the patient about the diﬀerence be-
tween the prescribed and dispensed pharmaceutical. Answering such questions
might be time-consuming, reducing the number of possible patient-visits per
day. This term could also express the strength of brand loyalty, reﬂected in a
non-pecuniary cost for allowing substitution away from a brand-name pharma-
ceutical, if for example the physician feels a moral responsibility to support the
ﬁrm that has invested in research to develop the pharmaceutical.
A principal-agent problem between patients and physicians arises because
physicians have private information about patients’ health (Blomqvist, 1991).
For notational simplicity, I illustrate this asymmetry in information by assum-
ing that the physician knows with certainty the diﬀerence in health outcome,
∆H, caused by the prescribed pharmaceutical versus the cheapest generic.13
12Remember that the patient had to pay the whole price-diﬀerence if they rejected substi-
tution.
13The diﬀerence in health eﬀect may arise, for example, if a patient was sensitive to inert
ingredients, or simply because a substitution to a pharmaceutical with another color or form
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Deﬁning θ as the patient’s copayment-rate and inserting ∆P and ∆H in equa-
tion (2) yields that the physician, if he/she knows that the patient would allow
substitution, would veto it if
γ1∆H − γ2∆Pθ− γ3∆P(1 − θ)+γ4c>0.( 3 )
If θ =1 , γ1 = γ2 and c =0 , equation (3) simpliﬁes to ∆H>∆P.T h a ti s ,i f
insurer cost is not aﬀected, the physician internalizes the patient’s health and
monetary cost equally and has no direct cost; then the physician would act as a
perfect agent for the patient.14 If θ 6=1and c 6=0 , the physician would only take
societally optimal decisions if γ1 = γ2 = γ3 = γ4.I fγ2 >γ 3, then the physician
is more likely to oppose substitution the lower the patient’s copayment-rate is,
that is, there is moral hazard in insurance.
If the physician knows that the patient would oppose substitution, the physi-
cian would only oppose it if
γ2∆P(1 − θ) − γ3∆P(1 − θ)+γ4c>0.( 4 )
If c =0 , equation (4) simpliﬁes to γ2 >γ 3 . Hence, the model shows how the
presence of moral hazard can be tested for by analyzing whether physicians were
more likely to oppose substitution when the patients’ copayment-rates were low.
The model also illustrates two set of reasons why private physicians might
be more inclined than county physicians to veto substitution, which can be
tested for. First, private physicians might have higher direct costs from allowing
substitution. If, as noted earlier, doing so requires more time per patient and
hence result in fewer patient-visits per day, this will be more costly for private
physicians since it will aﬀect their income. They might also have stronger
brand-name loyalty since they, as opposed to county-employed physicians, are
not restrained by their employer from participating in education organized and
paid for by pharmaceutical companies.15 If private physicians’ decisions are
aﬀected by either of these mechanisms, we would expect them to be more likely
to veto substitution irrespective of the patients’ copayments.
Second, private physicians might have stronger pecuniary incentives to please
their patients in order to keep them and/or attract new patients, which could
14γ1 could diﬀer from γ2 because of paternalism, for example, or fear that neglecting to do
what is best for the patient’s health might result in an oﬃcial complaint.
15Andréa Mannberg and Mikael Lindberg brought this possibility to my attention at a
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result in a greater diﬀerence between γ2 and γ3 for them compared to county-
employed physicians. As illustrated in the model above, this would have a larger
impact on the physician’s decision the lower the patients’ copayments are. Thus,
if this mechanism is operative, we would expect private physicians’ likelihood of
vetoing substitution to increase faster than that of county-employed physicians,
as patients’ copayments fall.
4 The empirical analysis
4.1 Data
The prescription dataset used in this study was provided by the county council
of Västerbotten, Sweden. It contains all prescriptions sold in the county, or sold
in other parts of Sweden to residents of the county, from January 2003 through
October 2006, except for November and December, 2003, and September, 2004.
Data for these three months are not available since the county council’s data
ﬁles for these months were damaged. Prescriptions issued before the substitu-
tion reform of October, 2002 and prescriptions of pharmaceuticals packed in
patient-doses, were excluded since in these cases physicians were not asked if
they opposed substitution.16 Non-pharmaceutical prescriptions as well as pre-
scriptions issued by others than physicians (e.g. dentist and nurses) were also
excluded. Finally, after excluding nearly 270,000 observations originating from
other workplaces than health centers, clinics or private practices in Västerbot-
ten (e.g. emergencies, labs, occupational health services, or workplaces in other
counties), or unknown workplaces, and 630,000 that lack data on ATC-group17
or did not belong to any ATC-group, 5.1 million observations of pharmaceutical
prescriptions remain.18
In 1.7 and 2.8% of the observations the physician and patient, respectively,
opposed substitution. All these observations were used plus a random sample
16Patients with stable medication, who might have some problem keeping track of how
much they should take, often receive their prescriptions in "patient-doses".
17In the World Health Organization’s Anatomical Therapeutic Chemical (ATC) classiﬁ-
cation system, pharmaceuticals are divided into groups according to the organ or system on
which they act, and their pharmacological, therapeutic, and chemical properties. In the ATC-
groups used here, pharmaceuticals with the same active ingredients are grouped together.
18U s i n ga l s oo b s e r v a t i o n sl a c k i n gA T C - g r o u pd a t a( i n c l u d i n gt h o s et h a td i dn o tb e l o n gt o
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of 2.5% of the remaining observations, resulting in a ﬁnal sample of 350,180
observations. A sample had to be drawn because of limited computer-capacity
for running iterative estimation procedures. Because of the low percentage of
physicians opposing substitution, all those observations were used in order to
reduce the variance in the logistic regressions, compared to using a random sam-
ple from the whole population, resulting in the same number of observations.19
A l lo b s e r v a t i o n sw h e nt h ep a t i e n t sr e f u s e ds u b s t i t u t i o nw e r eu s e di no r d e rt o
minimize the eﬀect of individual measurement-errors of the copayment variables
that may exist for these observations.20
Some descriptive statistics are presented in Table I, where the sample is
grouped based on whether the physician vetoed substitution (V =1 )o rn o t
(V =0 ). The observations are weighted according to the inverse of their
probability of being sampled. For the indicator-variables the percentage of
observations in each category are presented. For the continuous variable Age,
means and standard deviations are presented instead. The variables Private
and County take the value one if the prescribing physician worked at a small
private practice or was employed by the county, respectively, while the next
three variables indicate which healthcare district (Ume ˚ a, Skellefte˚ a or South
of Lapland) their workplace was located in.
The dataset includes information about the total cost of the prescription
as well as the patient’s copayment, from which the copayment-rate the pa-
tient had prior to paying for the current prescription was calculated (calcu-
lations are available from the author upon request). The indicator-variables
Copay100, Copay50, Copay25, Copay10 and Copay0 show these predetermined
copayment-rates. Some prescriptions are always free of charge (Free)f o rt h e
patient and others are excluded from the insurance system (Unsub) irrespective
of the patient’s copayment bracket. The last two variables refer to the gender
and age of the patient.
19Following Boyes, Hoﬀman and Low (1989) and Greene (1992) - who also over-sampled
observations where the dependent variable took the value one, because of the low share of such
observations in the population - I used sampling-weights in the estimations. Greene (2003,
Chapter 21) describes why sampling-weights should be used to avoid bias that otherwise
could arise because of choice-based sampling. In this study the same qualitative results were
obtained when sampling weights were not used, with the exception of the results for Copay10.
20These measurement errors can arise since ∆P cannot be perfectly observed. Excluding
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Table I. Descriptive statistics
Variable Sample V =1 V =0
V 1.68 100 0
Private 7.38 9.05 7.36
County 92.62 90.95 92.64
Ume ˚ a 54.69 64.49 54.52
Skellefte˚ a 28.63 22.46 28.73
Lapland 16.69 13.04 16.75
Copay100 36.05 25.17 36.24
Copay50 13.87 12.51 13.89
Copay25 11.04 11.06 11.04
Copay10 5.33 6.01 5.32
Copay0 29.59 43.60 29.35
Unsub 3.26 1.26 3.29
Free 0.85 0.39 0.86
Women 59.45 58.80 59.46
Age 59.17±20.19 61.93±17.58 59.12±20.23
Population size 5,112,236 85,678 5,026,558
Sample size 350,180 85,678 264,502
In addition, the dataset includes information about the prescribed pharma-
ceutical’s ATC-code, the patient’s municipality of residence, and the date when
the prescription was written. Of the 883 seven-digit ATC-groups present in the
sample, 276 have less than 10 observations; 334 have 10 to 100 observations;
206 have 100 to 1000 observations; and 67 have more than 1 000 observations.
36% of the prescriptions were written to inhabitants of Umeå, the county’s
largest municipality; 28% to inhabitants of Skellefteå; 1-5% to inhabitants of
each of the county’s other municipalities; and 3% to individuals not living in
the county. 1-3% of the observations were issued in each of the 49 months from
the substitution reform, eﬀective in October 2002, through October 2006.
The descriptive statistics provide some support for the hypotheses tested
here. First, private physicians are over-represented among the subsample where
substitution was vetoed. Second, the same is true for patients’ with low copay-
ments whereas the opposite is true for those with high copayments.
The dataset described above was linked with another dataset, provided byDoes physicians’ compensation aﬀect the probability ... 12
the company IMS Sweden, that classiﬁed 50% of the prescribed pharmaceuticals
as originals (here called brands).
4.2 Empirical speciﬁcation
The baseline empirical speciﬁcation (speciﬁcation 1) is
Pr(Vi =1 ) = F(a + β1Privatei +
4 X
c=1
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In all estimations, a maximum-likelihood logit estimator which adjusts for sampling-
probability was used.21 In addition, the error terms ( i) were allowed to be
heteroskedastic and correlated within workplace units.22,23
Privatewas included to test the main hypothesis in this study, that private
physicians were more inclined to veto substitution.24 The copayment-indicators
were included to test the hypothesis that moral hazard in insurance exists.
What really inﬂuences physicians’ decisions is probably their expectation of their
patients’ copayments at the end of the insurance period, since this determines
the share of the cost of a veto borne by the patient. This is not observable,
but those with a predetermined copayment-rate of 0% will also have a zero-rate
at the end of the insurance period. The other copayment-variables are only
proxies, since for example those with a predetermined copayment-rate of 25%
will have a rate of 25% or lower at the end of the insurance period.
21The same qualitative results were obtained when a probit estimator was used instead.
22For county-employed physicians, the workplace unit is the health centre or clinic where
they work. Private physicians are grouped together in the data to one workplace unit per
healthcare district. Allowing for this correlation is important since Hellerstein (1998), Coscelli
(2000) and Lundin (2000), among others, found persistence in physicians’ prescription behav-
ior.
23A Huber-White sandwich-estimator was used to calculate robust standard errors.
24I nt h eb a s e l i n es p e c i ﬁcation, prescriptions written at Dragonen’s health centre after it
became private were excluded since the incentives for those writing these probably diﬀered
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Predetermined copayment-rates were used in order to avoid endogeneity
caused by the value of the dependent variable for observation i aﬀecting the
value of independent variables for that observation. Nevertheless, persistence
can cause endogeneity. For example, a physician who previously vetoed substi-
tution of a particular pharmaceutical for a particular patient, might be more
inclined to veto substitution again the next time for the same patient and phar-
maceutical. At the same time, the past decision might aﬀect the patient’s
predetermined copayment-rate. To study whether this possibility aﬀects the
results, the baseline speciﬁcation was also estimated on a subsample of only
antibacterial drugs (ATC-group J01), since these are very seldom prescribed
repeatedly to a patient. Another problem that has to be kept in mind when
interpreting the results is that the copayment-variables are correlated with pre-
vious pharmaceutical expenditures.
Unsuband Freealso reﬂects copayments and were therefore included. How-
ever, pharmaceuticals that are always free of charge, or always excluded from the
insurance, belong to a small number of ATC-groups, with which these variables
are highly correlated, so high that some ATC-indicators were excluded from the
estimations due to multicollinearity. Therefore, the coeﬃcients for Unsub and
Freeprobably captured other eﬀects besides those relating to moral hazard.
Women, indicator-variables for 5-year age-groups, and the ATC-indicators
were used as proxies for diﬀerences in health outcome in which the prescribed
pharmaceutical and the cheapest generic might result.25 The ATC-indicators
also controlled for the fact that in some ATC-groups there are no generics, so
that the physicians’ willingness to allow substitution had no eﬀect.26 Finally, the
ATC-indicators controlled for heterogeneity among ATC-groups with respect
to price-diﬀerences between the prescribed pharmaceutical and the cheapest
available generic, ∆P. I did not directly control for ∆P since physicians might
25I also tested using the continues variables age and age-squared, as well as using larger age-
groups, and including date of prescription as a continues variable. The speciﬁcation presented
was chosen over these alternatives since it had a better (lower) value on the AIC information-
criterion. The qualitative results are the same regardless, including not controlling for ATC-
groups.
26Observations from these ATC-groups were used since descriptive statistics indicated that
physicians had imperfect information about which pharmaceuticals had substitutes; in this
sample they vetoed substitution in 21,000 cases where no substitutes existed. However, de-
scriptive statistics indicate that a veto against substitution was twice as likely when substitutes
existed. Excluding prescriptions whit no substitutes did not change the qualitative results.Does physicians’ compensation aﬀect the probability ... 14
decide simultaneously which pharmaceutical to prescribe and whether or not to
veto substitution. Endogeneity could therefore arise if ∆P were included in the
speciﬁcation.27
The municipality-indicators, including one variable indicating whether or
not the patient lived in the county of Västerbotten, were included, together
with the demographic variables, to capture socioeconomic diﬀerences among
the municipalities. Diﬀerences among municipalities might be important to
control for, since disproportionately many private physicians are located in the
two biggest municipalities, Umeå and Skellefteå. Also, I controlled for which
healthcare district the prescribing physician belonged to, and in which of the 17
quarters the prescription was written. The estimation results from the baseline
speciﬁcation are presented in the ﬁrst column of Table II (next section).
The theoretical model suggests that the eﬀect of a patient’s copayment-rate
on the probability of a veto will be stronger the higher the diﬀerence between γ2
and γ3, i.e., the greater the diﬀerence between how much the physician weight
the patient’s and insurer’s costs. If the diﬀerence was higher for private than
for county physicians, then interaction-terms between Privateand the six vari-
ables reﬂecting patients’ copayment-rates should be included. The estimation
results obtained when these interaction-terms were included (speciﬁcation 2)
are presented in the second column of Table II.
In the ﬁrst two speciﬁcations, private physicians are compared to county-
employed physicians, irrespective of whether they worked at health centers or
clinics. Estimation results for county-employed physicians alone indicate that
those working at clinics (primarily specialists) were more inclined to veto sub-
stitution than were those working at health centers (primarily general prac-
titioners, GPs). Nearly half of the private physicians, but less than 20% of
the county-employed physicians, were GPs. It is therefore quite possible that,
among private physicians, a higher share of prescriptions was written by GPs,
compared to those written by county-employed physicians. But since the data
does not indicate whether each individual prescription was written by a GP or
not, it is not possible to compare private and county-employed GPs separately,
and private and county-employed specialists separately.
If being a GP makes a physician less inclined to oppose substitution, then
27With the exception of Copay10, the qualitative results were not changed by including ∆P
separately or interacted with the copayment-variables.Does physicians’ compensation aﬀect the probability ... 15
the odds-ratios for Privatein the ﬁrst two speciﬁcations will be underestimated,
and can then be understood as lower bounds. In speciﬁcation 3 (and speciﬁ-
cation 4), upper bounds were estimated by including an indicator-variable that
takes the value one for prescriptions written at clinics, so that only physicians
working at health centers were used as a control group for the private physicians.
The fourth column in Table II presents the results obtained by comparing
physicians working at Dragonen’s health center with physicians at other health
centers. This speciﬁcation includes an indicator-variable for all prescriptions
written at Dragonen’s health center and another for prescriptions written there
after it became private (Dragonen’spost). The latter was included to help test
the hypothesis that private physicians were more likely to veto substitution.
4.3 Results
The estimation results in Table II are presented in terms of odds-ratios.28 Since
physicians vetoed substitution in less than 2% of the cases, the odds-ratio is
approximately equal to the relative probability evaluated at the mean value of
each independent variable.29
The point estimates from the ﬁrst two speciﬁcations indicate that on average
private physicians were approximately 50% more likely to oppose substitution,
compared to county-employed physicians, ceteris paribus. As noted that is a
lower bound. The corresponding ﬁgure for the upper bound, obtained from
the last two speciﬁcations, is about 80%. The diﬀerent estimates regarding
Privateare not signiﬁcantly diﬀerent from each other, but all are signiﬁcantly
diﬀerent from unity at the 5% level, and thus provide clear support for the main
hypothesis in this paper.
A second purpose of the study was to analyze moral hazard in insurance.
The odds-ratios increase as the patients’ copayment decreases. This can indicate
moral hazard but, as noted, can also have other explanations. The same pattern
was observed when restricting the sample to only antibacterial drugs, except
28The odds-ratio for an independent variable X is [Pr(V =1 ) |(X =1 ) /Pr(V =0 ) |(X =
1)]/ [Pr(V =1 ) |(X =0 ) /Pr(V =0 ) |(X =0 ) ] . Hence, an odds-ratio of one means that the
variable X does not aﬀect the probability of a veto.
29Formally, as Pr(V =0 )approaches 1, the odds-ratio for a variable X approaches the
relative probability; that is, Pr(V =1 ) |(X =1 ) /[Pr(V =1 ) |(X =0 ) .Does physicians’ compensation aﬀect the probability ... 16
Table II. Estimation results, odds-ratio
1234
Private 1.50∗∗ 1.54∗∗∗ 1.79∗∗∗ 1.75∗∗∗
(0.24) (0.23) (0.25) (0.25)
Copay50 1.18∗∗∗ 1.18∗∗∗ 1.16∗∗∗ 1.16∗∗∗
(0.03) (0.03) (0.03) (0.03)
Copay25 1.31∗∗∗ 1.32∗∗∗ 1.28∗∗∗ 1.28∗∗∗
(0.04) (0.04) (0.03) (0.04)
Copay10 1.39∗∗∗ 1.38∗∗∗ 1.35∗∗∗ 1.35∗∗∗
(0.04) (0.04) (0.04) (0.04)
Copay0 1.97∗∗∗ 1.99∗∗∗ 1.85∗∗∗ 1.85∗∗∗
(0.14) (0.15) (0.09) (0.09)
Unsub 1.35∗∗∗ 1.32∗∗∗ 1.34∗∗∗ 1.33∗∗∗
(0.13) (0.12) (0.13) (0.13)
Free 2.46 0.89 0.82 0.83
(1.90) (0.52) (0.44) (0.44)
Women 1.10∗∗ 1.10∗∗ 1.13∗∗∗ 1.13∗∗
(0.05) (0.05) (0.04) (0.04)
Skellefte˚ a 0.68∗∗∗ 0.68∗∗∗ 0.77∗∗ 0.76∗∗
(0.09) (0.09) (0.09) (0.09)
Lapland 0.53∗∗∗ 0.53∗∗∗ 0.66∗∗∗ 0.64∗∗∗



















AIC 50,891 50,889 50,668 51,077
Pseudo R2 0.1434 0.1434 0.1471 0.1479
Sample size 346,381 346,384 346,384 349,073
Notes: The asterisks ***, ** and * denote signiﬁcance at the 1%, 5% and 10% levels.
Robust standard errors are shown in parentheses.
Estimation results for age-, ATC-groups, municipalities and quarter of prescription
are suppressed in order to save space, but are available from the author upon request.Does physicians’ compensation aﬀect the probability ... 17
that the odds-ratio for Copay25 was below unity, though not signiﬁcantly so
(odds-ratio 0.93; std. err. 0.22). Because of increased standard error, the
only copayment estimate that was found to be signiﬁcantly diﬀerent from unity
was that for Copay0 (odds-ratio 2.39; std. err. 0.51).30 Thus at least the
results regarding copayments do not seem to be driven solely by persistence in
the physicians’ prescription decisions. However, one cannot conclude whether
the results are driven by previous pharmaceutical expenditures and/or moral
hazard. An argument for the former is that high pharmaceutical expenditures
are probably positively correlated with the number of diﬀerent pharmaceuticals
a patient consumes, and that a high number of pharmaceuticals can be a valid
reason for a physician to veto substitution, e.g., due to the risk that the patient
otherwise confuse the drugs. On the other hand, the nearly linear relationship
with the patients’ copayments that the estimates for Copay50, Copay25 and
Copay10 show suggest that the results might be driven by moral hazard. That
this pattern is broken by the high point estimates for Copay0 can be explained
by less measurement-error for that variable, and hence less attenuation.
As mentioned, the variables Unsub and Free are highly collinear with sev-
eral ATC-groups, and the estimates for these variables should therefore be in-
terpreted with caution. The results suggest that physicians were more inclined
to veto substitution for pharmaceuticals which were always unsubsidized, com-
pared to other pharmaceuticals where the patients’ copayments were 100%. The
odds-ratios for pharmaceuticals that were always free of charge were unstable
and not signiﬁcantly diﬀerent from unity. This is probably due to the collinear-
ity problem.
That the patient was a woman was found to increase the probability of a
veto. Physicians in the healthcare districts of Skellefteå and South of Lapland
were less inclined to veto substitution than those in the omitted healthcare
district (Umeå). Estimation results for age-, ATC-groups, municipalities and
quarter of prescription are not reported in order to save space, but are available
from the author upon request. A Wald test (not reported) shows that these
groups of variables had signiﬁcant eﬀects.
Among the interaction-variables included in the second speciﬁcation, only
the interaction with Unsub was signiﬁcantly diﬀerent from unity.31 Thus the
30The estimates for Copay50 and Copay10 are 1.16 (0.21) and 1.31 (0.31). Full results from
this sample are available from the author upon request.
31The diﬀerentials of the odds ratios with respect to the variable Private and the sixDoes physicians’ compensation aﬀect the probability ... 18
results do not indicate any diﬀerences between private and county-employed
physicians regarding the degree to which they internalize patients’ costs rela-
tive to the insurer’s costs. Hence, the fact that private physicians were more
likely to veto substitution does not seem to depend on them wanting to please
their patients. Rather, the results suggest that the diﬀerence between the two
physician groups can be explained by diﬀerences in direct costs associated with
substitution. Estimation results (not reported) show that the diﬀerence between
private and county-employed physicians’ likeliness of vetoing substitution was
approximately ﬁve times higher when brand-name pharmaceuticals were pre-
scribed, compared to non-brand name ones. This indicates that a large part of
the diﬀerence between the two physician groups might be explained by private
physicians having stronger brand-name loyalty.
The results from the third and fourth speciﬁcations clearly show that substi-
tution was more likely to be vetoed if the prescription was written at a clinic in-
stead of a health center. As mentioned, the point estimates for Privatebecame
larger when controlling for Clinic. The estimated odds-ratios for the healthcare
districts became closer to unity, which makes sense since a disproportionably
high share of the prescriptions originating from the omitted healthcare district
(Ume ˚ a) were written at clinics. Controlling for Clinic also resulted in slightly
lower odds-ratios for the copayment variables.
The hypothesis that private physicians were more inclined to veto substi-
tution was given further support by the results regarding Dragonen’s health
center, reported at the bottom of the last column. Physicians there became
approximately 50% more likely to veto substitution when the center became
private.32 However, even though nearly 3000 prescriptions in the sample origi-
nated from this health center after it became private, it is still only one health
center. Thus the pattern found is only the result from one case study. An advan-
tage of studying this center though is that the data includes observations from
variables reﬂecting patients’ copayments, are Private: 1.52 (0.24); Copay50:1 . 1 8 ( 0 . 0 3 ) ;
Copay25: 1.31 (0.04); Copay10: 1.39 (0.04); Copay0:1 . 9 7( 0 . 1 4 ) ;Unsub:1 . 3 5( 0 . 1 2 ) ;Free:
0.91 (0.52).
32Since physicians working at this health centre knew before June 2006 that it would be
privatized, it is possible that they started to adjust to the reform before that date. There-
fore speciﬁcation 4 was estimated excluding observations written at Dragonen’s health center
between February 2006 - when the contract regarding privatization of the health centre was
signed - and June 2006. This did not change the qualitative results, but the estimate for
Dragonen’spost became slightly larger, 1.57 (0.10).Does physicians’ compensation aﬀect the probability ... 19
both before and after it was privatized. Therefore time invariant heterogeneity
regarding the health center can be controlled for.
5 Discussion
The importance of the form of compensation that physicians receive and the
presence of moral hazard in insurance were analyzed by studying the determi-
nants for whether physicians vetoed substitution or not.
The primary purpose was to test if physicians working at private practices
were more likely to oppose substitution than county-employed physicians work-
ing on salary. It was found that private physicians were indeed more likely to
veto substitution. Depending of how the control group was speciﬁed private
physicians were estimated to be 50-80% more likely to veto substitution. Also
the results show that physicians working at Dragonen’s health center became
approximately 50% more likely to veto substitution when the center became
private.
The diﬀerence in the likeliness of private and county-employed physicians
vetoing substitution was not signiﬁcantly aﬀected by patients’ copayment-rates.
This suggests that the observed diﬀerence between the two physician groups was
caused by diﬀerences in direct costs associated with substitution, rather than
private physicians being more inclined to please their patients in order to secure
a high number of patient-visits. There could be such a diﬀerence if, as seems
possible, private physicians have stronger brand loyalty. Allowing substitution
might also be time-consuming for the physician, if it worries the patient. Hence,
it could reduce the number of patient-visits per day, which would be more costly
for private physicians, since their income depends on that number.
Since a physician can choose whether or not to work privately, it cannot be
ruled out that the pattern found was caused by selection: The physicians who
chose to work privately might have diﬀered systematically from those that did
not, for example, they might have had stronger brand-name loyalty already be-
fore becoming private physicians. Similarly, patients that chose to visit private
physicians might have had systematic unobserved diﬀerences from those that
did not.
A second purpose was to analyze if moral hazard in insurance aﬀected the
physicians’ decisions, that is, if physicians internalized costs borne by their pa-Does physicians’ compensation aﬀect the probability ... 20
tients more than costs borne by the insurance. The results are consistent with
that moral hazard aﬀected the physicians’ decisions, and the point estimates
imply that physicians were nearly twice as likely to oppose substitution if all
costs were borne by the insurance rather than by the patient. Thus physicians
appeared to act more as agents for their patients than for the insurer. The
patients’ copayment-rates are a function of their previous pharmaceutical ex-
penditures, however, so it cannot be ruled out that the results were caused, for
example, by physicians being more likely to veto substitution the more phar-
maceuticals a patient was using.
A veto against substitution not only leads to higher cost for the current
prescription but also risks reducing price-competition between pharmaceutical
ﬁrms. Therefore these results are important to consider when designing physi-
cians’ contracts, and perhaps also when designing pharmaceutical insurance.
However, more research is needed, especially regarding moral hazard in insur-
ance, preferably based on data where patients can be followed over time so that
persistence in pharmaceutical consumption can be studied and the number of
pharmaceuticals a patient consumes can be controlled for. Further research
about physicians’ compensation should preferably be based on data where the
share of private physicians is largely aﬀected by policy changes, so that selection
eﬀects can be separated from treatment eﬀects.Does physicians’ compensation aﬀect the probability ... 21
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